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Abstract
Background: Opioid addiction is a chronic, relapsing disease and remains a major public health challenge.
Despite important expansions of access to conventional treatments, there are still significant proportions
of affected individuals who remain outside the reach of the current treatment system and who contribute
disproportionately to health care and criminal justice costs as well as to public disorder associated with
drug addiction.
The NAOMI study is a Phase III randomized clinical trial comparing injectable heroin maintenance to oral
methadone. The study has ethics board approval at its Montréal and Vancouver sites, as well as from the
University of Toronto, the New York Academy of Medicine and Johns Hopkins University.
The main objective of the NAOMI Study is to determine whether the closely supervised provision of
injectable, pharmaceutical-grade opioid agonist is more effective than methadone alone in recruiting,
retaining, and benefiting chronic, opioid-dependent, injection drug users who are resistant to current
standard treatment options.
Methods: The case study submitted chronicles the challenges of getting a heroin assisted treatment trial
up and running in North America. It describes: a brief background on opioid addiction; current standard
therapies for opioid addiction; why there is/was a need for a heroin assisted treatment trial; a description
of heroin assisted treatment; the beginnings of creating the NAOMI study in North America; what is the
NAOMI study; the science and politics of the NAOMI study; getting NAOMI started in Canada; various
requirements and restrictions in getting the study up and running; recruitment into the study; working with
the media; a status report on the study; and a brief conclusion from the authors' perspectives.
Results and conclusion: As this is a case study, there are no specific results or main findings listed. The
case study focuses on: the background of the study; what it took to get the study started in Canada; the
unique requirements and conditions of getting a site, and the study, approved; working with the media;
recruitment into the study; a brief status report on the study; and a brief conclusion from the authors'
perspectives.
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Background
Opioid addiction is a chronic, relapsing disease and
remains a major public health challenge in North America
with an estimated 80,000 opioid users in Canada alone
[1]. It is estimated that there are 20,000 opioid dependent
persons in Vancouver and at least 6,000 in Montréal, these
representing only two of Canada's larger cities [1]. Despite
important expansions of access to conventional treat-
ments, there are still significant proportions of affected
individuals, many with multiple co-morbidities, who
remain outside the reach of the current treatment system
and who contribute disproportionately to health care and
criminal justice costs as well as to public disorder associ-
ated with drug addiction [2].
Untreated opioid addiction can lead to overdose, infec-
tious diseases, loss of regular social and economic func-
tioning, and extensive engagement in both drug-related
and drug acquisition crime [3-6]. Opioid addiction is also
highly correlated with mental illness and the combination
of these two is a predictor of poorer treatment outcomes
[7-9]. At a societal level, there are associated costs to pub-
lic health and health care as well as to the welfare and
criminal justice systems in dealing with these risk and
harm phenomena. In Canada, illicit drug use costs in
2002 were estimated at $40 billion or $1,267 per capita
with the three highest contributors being loss of produc-
tivity, direct health care and law enforcement [10]. In
1996, Vancouver's Medical Health Officer reported that
the increase in injection drug use seen in Vancouver was
resulting in an increased incidence of HIV/AIDS and Hep-
atitis, increased hospital and emergency service utilization
for treatment of HIV-related diseases, septicaemia and
endocarditis, as well as increased ambulance responses
and emergency room visits related to drug overdoses. In
addition, the report noted a related increase in fetal expo-
sure to addictive substances, increased pressure on com-
munity-level outreach nursing and medical services, and
an increased need for community-level hospice palliative
care [11].
Methadone maintenance therapy (MMT) has been the pri-
mary substitution treatment for opioid addiction in North
America since the 1960's [12,13]. MMT efficacy has been
largely proved with respect to various outcomes [14-17] –
it decreases the cravings, decreases the number of injec-
tions, and can sometimes lead to abstinence. However,
like other treatments for diseases such as cancer or HIV,
MMT is not effective for everyone. Some patients on MMT
are not retained long enough to benefit from the program
or show limited response, continuing to use illicit drugs
outside of the treatment setting [18]. Several factors have
been highlighted as predictors of lack of efficacy of MMT
or barriers to access (and retention) in the program [19-
25]. These include: inadequate methadone doses; user
fees; punitive urine testing (e.g. complete abstinence from
any drug use required for continued MMT); and lack of a
'high' associated with MMT. While many of these factors
can be improved upon, even when MMT is optimally
delivered (i.e. high dosage, psychosocial support, treat-
ment of co-morbidities), there remains a sub-sample of
between 15% and 25% of patients who do not benefit
from this treatment [26,27]. For example, the MMT group
in the German Heroin Assisted Therapy (HAT) trial
received an optimized version of MMT (compared to what
is available in their communities) and still 30% and 50%
were considered 'non-responders' with respect to their
health and illicit drug use scores respectively [28]. As such,
MMT is effective but can be sub-optimal and it is not
always successful.
Buprenorphine, particularly suboxone (a combination of
buprenorphine and naloxone) – a partial agonist, has
been approved in the United States, and recently in Can-
ada, for substitution therapy. While there is limited data
on the effectiveness of this treatment in addiction therapy,
use of suboxone has shown that it may only be truly effec-
tive for those who use low doses of opioids or who are on
low doses of methadone. In fact, a recent review of 13
clinical trials, 12 of which were double blind, comparing
buprenorphine maintenance with either placebo or MMT
for opioid dependence concluded that buprenorphine
appeared to be significantly less effective than methadone
in retaining patients in treatment [29].
Why the need for a HAT trial?
The first question that can be asked is 'Is there really a
need for a trial of heroin assisted therapy?' The need for
such a trial was noted in the Le Dain Commission's Report
in 1972 [30]. This report was produced by the Canadian
Government Commission on Inquiry into the Non-Med-
ical Use of Drugs. Included in this report is a recommen-
dation for the "implementation of a heroin prescription
trial for addicts who could not be attracted into conven-
tional forms of opioid addiction treatment".
In the United Kingdom (UK) heroin prescription has been
part of the addiction treatment system since 1926 [30-32].
In the nineties, Switzerland opened heroin assisted treat-
ment (HAT) clinics in response to the public health prob-
lem caused by the use of illicit heroin [33,34]. The Swiss
experience showed that heroin prescription delivered
under supervision in clinics was both safe and feasible
[33,34]. Moreover, these patients improved their health,
reduced their use of illicit drugs and illegal income, and
also committed fewer drug and property related offences
[35,36]. These improvements were sustained over time,
even after leaving the treatment [37]. In 1999 a World
Health Organization's expert panel issued a report in
which they recognized this success; however, the panelHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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also felt that it was not possible to determine whether
these improvements were due to HAT or the ancillary psy-
chosocial services that the participants received [38].
After the success of the Swiss model, several European
countries followed their initiative. The Netherlands, Ger-
many and Spain, followed later by Canada and the UK,
implemented randomized controlled HAT trials in order
to better answer the question of the effectiveness of super-
vised HAT in their contexts [26-28,39-41]. In addition, in
2008 Denmark announced the approval of HAT as part of
their addiction treatment program and Belgium started a
Randomized Controlled Trial (RCT) comparing injected
and inhaled heroin (Dutch model [26]) versus oral meth-
adone. The Dutch, German and Spanish trials results
showed that HAT was more effective than oral MMT in the
areas of improved health, psychosocial adjustment and
illicit drug use among long-term, socially excluded her-
oin-dependent people who were not benefiting from the
available treatments [26-28,40].
In Switzerland and the Netherlands, HAT is now part of
the addiction treatment system, and Germany is in the
process of requesting registration for diamorphine
(DAM). However, in Spain the government denied the
request of HAT for opioid-dependence treatment and cur-
rently only allows it under compassionate use.
Although evidence is building that HAT is an effective
treatment alternative for opioid dependence, more work
is still to be done. Even with the study results on HAT cur-
rently published, many countries still do not support the
use of heroin as a treatment option for opioid dependence
largely due to the stigma associated with this drug, as well
as the politics associated with treating those dependent on
heroin with heroin. Some feel that while HAT worked in
some countries, it may not work in their own because of
different cultural and societal issues.
While Denmark approved HAT without a clinical trial,
Belgium researchers have been trying for some time to get
HAT approved and, at this point, only have approval for a
RCT using MMT as an active comparator. In Switzerland,
the provision of HAT was approved after a referendum
was passed and the German trial went ahead only after a
change in their government. In Spain, the debate went on
for years before a RCT of HAT was approved. Thus, despite
the recommendations made by the Le Dain Commission
so many years ago, the successful experiences in other
countries, and that addiction treatment policies, like any
medical or public health practice, should be evidence
based – and evidence does exists [42], the only hope of
possibly having DAM registered as a treatment for opioid
addiction in Canada meant that a RCT of HAT was needed
to examine whether HAT would be effective in the Cana-
dian context.
Understanding HAT
Heroin (injected) assisted treatment is aimed at a very
select group of opioid users. The target population for
HAT have been using heroin (or other illicit opiates) for
several years, have severe health and psychosocial prob-
lems associated with their drug use, and have not bene-
fited currently or in the past from available therapies such
as MMT. HAT should not be considered as a replacement
for MMT or buprenorphine, but rather as an additional
treatment option for a specific sub-population and for
whom MMT and/or buprenorphine have not been effec-
tive. Supervised HAT clinics require daily visits (up to 3
per day) and participants are subject to close monitoring
and evaluation while in the clinic. Medically prescribed
heroin, while provided at no cost to participants, is not
'free heroin' as it is a tightly controlled and very demand-
ing treatment [43,44].
If one considers the Swiss HAT treatment model as a ref-
erence, with 23 clinics working at 91% capacity, HAT
accounts for 8% of the substitution treatment [45] being
provided in that country. Thus, HAT is clearly an alterna-
tive for the most vulnerable and severely affected popula-
tion of opioid dependent people, who, without HAT
treatment, would likely remain outside of the treatment
system. The amount of attention and controversy around
this treatment, given this important but circumscribed
role within the realm of addiction treatment, is to say the
least, disproportionate [46].
NAOMI – the early days
In September 1998 the first North American Opiate Med-
ication Initiative (NAOMI) Working Group was formed
with treatment experts, research scientists and bio-ethi-
cists from both the US and Canada. The mandate of the
group was to examine HAT as a treatment modality for
chronic opiate-dependence and, if thought feasible,
develop a scientifically rigorous and ethically defensible
study proposal.
The NAOMI Working Group held a series of protocol
design meetings from 1998 to 2000 during which time a
six-centre RCT proposal was developed. Three sites were
to be established in Canada (Vancouver, Toronto and
Montréal) with the other three to be established in the US.
In 1999 an external international review panel was com-
missioned by the investigators to review the proposal
while at the same time discussions were being held to
identify possible sites and funding in the US. As time went
on, it became increasingly clear that no US sites would be
able to participate nor could any US funding be identified.
As a result, the Canadian investigators decided to apply as
a Canadian three-site study to the Canadian Institutes of
Health Research (CIHR), and the NAOMI study was offi-
cially born.Harm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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NAOMI – what is it?
The NAOMI study is a Phase III RCT comparing injectable
opioid agonist maintenance (primarily with heroin but
also with hydromorphone) to oral methadone. The study
is funded by CIHR, Canada's premier scientific research
funding body, and has ethics board approval at its Mon-
tréal (Université de Montréal) and Vancouver (University
of British Columbia and Providence Health Care) sites.
The study also received ethical approval from the Univer-
sity of Toronto, the New York Academy of Medicine and
Johns Hopkins University.
The main objective of the NAOMI Study is to determine
whether the closely supervised provision of injectable,
pharmaceutical-grade heroin is more effective than MMT
alone in recruiting, retaining, and benefiting chronic, opi-
oid-dependent, injection drug users (IDUs) who are
resistant to current standard treatment options.
The final version of the NAOMI study was a two-site study
(Montréal and Vancouver) with 251 participants rand-
omized to receive either injectable opioid or methadone
for 12 months of treatment (plus 3 months of transition
off of injectable medication), plus 12 months of research
follow up. Participants randomized to the injection arm
self-injected medications under the supervision of clinic
staff and could add oral methadone at any time during
their treatment in consultation with their physician. The
target population for NAOMI included men and women
over the age of 25 who were chronic, opioid dependent,
daily IDUs and who had previously failed MMT. Further
information on the trial design and methodology are
described elsewhere [47].
NAOMI – science vs. politics
The line between science and politics can be blurred at
times. Generally, researchers are most concerned with the
best science; however, in addiction research, getting a RCT
approved and funded sometimes means that certain com-
promises must be made. This can prove to be challenging,
as was the case with NAOMI, as researchers worked to
design a study that would be politically acceptable while
at the same time maintaining scientific integrity and
ensuring that the protocol would be scientifically rigor-
ous. This issue brought the distinction between pharma-
cology and phenomenology to the forefront of explaining
and educating people on opioid addiction.
The harms of heroin use can be categorized into two
classes, pharmacological and phenomenological. Phar-
macology refers to the science of drugs, including their
composition, uses and effects, while phenomenology
incorporates the fact that events and peoples' lives occur
in a complex and multi-faceted environment where the
socio-political systems affect people's lives. The pharma-
cological harms associated with heroin use include:
euphoria and/or sedation; withdrawal; constipation; and
flushing, many of which are also associated with other
commonly prescribed opioids. However; the phenome-
nological harms associated with heroin use, the ones most
often discussed, include: overdose; viral infections; bacte-
rial infections, violence, illegal activity; and social disinte-
gration. The latter are not attributable to the
pharmacology of the drug but rather to drug prohibition
which leads to the use of dirty needles, unsanitary/non-
sterile water, crime, prison, disease and overdose. The
question that comes to mind is 'What if all these 'addi-
tives' were removed from street heroin? What would be
left?' The answer is diacetylmorphine or DAM, the active
opioid contained in heroin.
Heroin has a documented history of being prescribed and
used as an analgesic dating back to at least 1901 when
Bayer®  Pharmaceutical Products were marketing it.
Between 1919 and 1923 there were several morphine and
HAT clinics operating in the USA until their termination
by the US government. By 1926 UK physicians were offi-
cially allowed to prescribe heroin; however, limitations
and controls were placed on heroin prescription in 1965
resulting in only limited numbers of patients being cur-
rently prescribed heroin in the UK [32].
Due to the controversial nature of the drug being tested in
NAOMI, the study design of the protocol was driven in
some places, specifically in the design of the eligibility cri-
teria for the study. For example, the study could not
recruit participants currently in MMT or who had been in
MMT in the prior 6 months because of the 'fear' that some
individuals would drop-out of treatment in order to apply
for the NAOMI trial. This criterion was an amendment to
the original protocol in response to health authorities and
MMT providers. In contrast, two of the other trials pub-
lished on HAT required that participants 'must' be on
MMT in order to participate because HAT was projected to
become part of the addiction treatment system. As a
result, many advocates and drug users felt that the NAOMI
study entry criteria were far too restrictive and that, if the
intent was to truly help this largely underserved popula-
tion, the criteria should be more flexible and inclusive.
Another somewhat political NAOMI issue was the with-
drawal of the Toronto site from the study. Construction
had begun at the Toronto site; however, they experienced
various delays in the renovation process. This together
with the previous commitment of the Toronto site to run
another study in the renovated clinic before they could
start NAOMI, meant that there would be a significant time
delay between when Toronto could start the trial and
when the other two sites would be starting. In addition,
there was a lack of consensus amongst the physicians andHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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researchers at the Toronto site as to whether heroin or
diverted prescription opioids were really the primary issue
in that city. This lack of consensus then extended to the
feasibility of the Toronto site being able to fully recruit
into NAOMI and what the potential value of HAT would
be in the Toronto context. Interestingly, a 2003 paper
written by researchers from the Centre for Addiction and
Mental Health in Toronto (CAMH) analyzing a popula-
tion survey conducted amongst adults residing in Ontario
regarding public opinion of safe injection facilities and
HAT showed that 62.3% of participants questioned felt
that medically prescribed heroin should be available for
long-term heroin addicts who have tried and failed all
other treatment options [48].
NAOMI in Canada
The NAOMI protocol was submitted to CIHR in March
2001; however, at the time CIHR was not able to provide
full funding for the trial. Consequently, CIHR spent sev-
eral months trying to identify additional sponsors. (The
US National Institutes of Health (NIH) were approached
but declined to co-sponsor the study.) In January 2002
full funding approval was granted for NAOMI after CIHR
received an overall funding increase.
An important point to note about the NAOMI study is
that, unlike its counterparts in Europe, NAOMI was cre-
ated and conducted by private citizens. In contrast, the
European HAT studies were government initiated and
thus already had the support of government and funding
bodies. This distinction is important in understanding
many of the hurdles in starting recruitment and treatment
into this type of study in North America.
With CIHR approval and funding in hand, a Clinical Trial
Application (CTA) needed to be written for submission to
the Regulatory Branch of Health Canada. Since there was
no pharmaceutical company 'sponsor' for the NAOMI
study, the Principal Investigator became the sponsor and
thus the study team prepared and submitted the CTA.
During this somewhat lengthy process, the first hurdle
(aside from funding) appeared. The study team was
informed that the bulk powder form of heroin that had
been planned to be used for the study was not acceptable
to Health Canada due to contamination/sterility con-
cerns. Instead, Health Canada required that the narcotic
be imported in lyophilized/freeze-dried form resulting in
a cost that was approximately eight times more expensive
than originally planned.
Final CTA approval for the study was granted in January
2003, which enabled the team to focus on the next steps
of getting the trial up and running, specifically identifying
study sites, seeking import/export permits for the heroin/
DAM, and obtaining a special section 56 exemption to
Canada's Narcotics Control Act to allow the team to import,
receive, and administer the heroin/DAM without the staff
or participants being arrested. This is the same exemption
that Vancouver's Supervised Injection Site required/s;
however, the requirements to obtain this exemption var-
ied greatly between the NAOMI study and the Supervised
Injection Site (also know as Insite).
Identifying study sites
It was thought that identifying study sites would be a rel-
atively straightforward and uncomplicated task, as was the
case with the Montréal study site. However, identifying a
Vancouver study site was anything but uncomplicated.
One of the first sites discussed for Vancouver was St. Paul's
Hospital, the city's inner-city hospital, which predomi-
nantly deals with Vancouver's IDU population. However,
at the outset multiple concerns were raised. First, St. Paul's
Hospital is a Catholic Hospital and, as such, was fearful
(at the time) about being perceived as condoning or sup-
porting injection drug use; Second, there was concern by
the hospital that having the study site located within its
walls would result in those addicted to heroin moving
into the neighbourhood in order to have easier access to
the site, known as the 'honey pot effect'; and finally, after
further consideration, it was the study team's feeling that
having the site at St. Paul's Hospital would be an impedi-
ment to participation as the target population would have
to travel three times per day to get to the site. Although the
hospital is only located 1.25 miles away from the current
site in Vancouver's Downtown East Side (DTES),
NAOMI's target population is deeply rooted in this com-
munity due largely to poverty, housing, welfare, and
stigma issues.
Vancouver's DTES is often described as the "poorest urban
postal code in Canada" and is home to approximately
5,000 IDUs. The median household income in the DTES
in 1996 was $12,900 compared to the City average of
approximately $48,000 [49]. According to a March 31,
2008 Expert Advisory Committee report to Canada's Fed-
eral Minister of Health, results based on 1,000 users sur-
veyed in the DTES showed that 20% are homeless and
many more live in unstable and/or single resident rooms.
80% have been incarcerated at some point, 38% are
involved in the sex trade, 59% reported a non-fatal over-
dose in their lifetime and 51% used heroin as their pri-
mary drug of choice. A report prepared by Coroner J.V.
Cain (Report on the Task Force into Illicit Narcotic Overdoses
in British Columbia) [50] reported that overdose deaths in
Vancouver had risen from sixteen in 1987 to two-hundred
in 1993. In 1997 researchers at the British Columbia Cen-
tre for Excellence in HIV/AIDS reported that the preva-
lence rate of HIV/AIDS in the DTES had reached epidemic
proportions and was 27% among injection drug users at
the time. In a September 1997 report by the Chief Medical
Health Officer of the Vancouver Richmond Health BoardHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
Page 6 of 14
(page number not for citation purposes)
it was reported that many individuals in the DTES were
coping simultaneously with poverty, lack of affordable
housing, lack of transportation, inter-generational abuse
and violence, and poor access to services. The majority of
users in the DTES are either on welfare, are unemployed,
or do not qualify for welfare. These factors make travel to
St. Paul's Hospital up to three times per day, seven days
per week, 365 days per year, a significant challenge. Based
on this and other circumstances, it was decided that the
study site should be established in the DTES.
Identifying a final study site in Vancouver took almost two
years. During this time many sites were considered. Some
were proposed by the local health authority, some pro-
posed by local service organizations, and others found by
members of our team walking the streets of the DTES
looking for vacant buildings. Unfortunately, the sites ini-
tially identified in the DTES all had one major issue in
common, they all required large amounts of renovations,
often estimated at close to $1 million Cdn worth, just to
be able to obtain an occupancy permit. Moreover, this $1
million price tag often did not include the cost of the sig-
nificant safety and security additions that the government
would require in order to obtain the necessary Section 56
exemption to legally store and administer the drug.
The first viable potential site identified was located in a
neighbourhood just on the outer edge of the DTES. This
site was centrally enough located so that the participants
could easily access it, and was also manageable in terms of
renovation costs. However, some members of the local
community had concerns about having the site for this
type of clinical trial in their backyard (the 'Not in My
Backyard' or NIMBY issue) and thus petitioned the City
against our use of it. In its reasons for not wanting the
NAOMI site in their neighbourhood, the community cited
that they felt that the overall area already housed many
service organizations and, thus, did not need another one.
Because of these issues, this site had to be abandoned.
It took nine months from that point to identify, secure,
and sign a lease for what is now the site of the Vancouver
NAOMI clinic. This site is in the heart of the DTES in a
former bank, complete with a vault, thus reducing some
of the renovation expenses in terms of the requirements
for the Section 56 exemption. In order to proceed with
renovations, the Vancouver study team needed to apply to
the City of Vancouver for a development permit. At the
time, the study team thought that this process would be
relatively painless as the site was not in a predominantly
residential neighbourhood; however, once again the site
became a political issue as some residents had concerns
about the site, specifically the NIMBY issue and the
number of service organizations already in operation in
the DTES. This resulted in our application having to go to
a full City Development Board review. The review process
resulted in the need for a public City Development Board
meeting to be called where both the study team and con-
cerned residents could voice their feelings. Within a few
months the meeting was convened and concerns in the
community had died down resulting in only two people
attending the meeting to speak out against the site loca-
tion. With the backing of some local service organiza-
tions, including the invaluable support of Vancouver's
Police Department, approval of our application was
granted and renovations could start; however, not without
some unique conditions.
City conditions for the Vancouver site
In response to the community's initial concerns, and
given the challenges that the City of Vancouver (and other
cities) face in managing the broader environment of facil-
itating increased services in a neighbourhood that already
is perceived by many to have too many services, some spe-
cific conditions were attached to the development permit
approval of the Vancouver site by the City of Vancouver,
including: 1) A twenty-four hour emergency contact tele-
phone number be established and posted on the doors of
the site as well as distributed to the community so that, in
the event that members of the local community had any
concerns, they could contact the study team at any time. It
is noteworthy that this line did not receive a single call
with a complaint about the study site. 2) The study team
had to guarantee that there would not be line-ups out
front of the clinic at any time and, should such occur, the
team would disperse the line up. This is a demonstration
of some of the stigma that affects this already marginal-
ized group, especially given that businesses, such as ticket
stores, box offices and electronics store, as well as busi-
nesses that serve alcohol such as bars, lounges and night
clubs, are generally allowed to have line ups in front of
their establishments. 3) The study team had to develop a
'Good Neighbour Agreement' which each participant was
required to sign upon receiving their designation (injecta-
ble opioid or methadone). This agreement required the
participants to agree that they would not loiter near the
clinic, not line up outside of the clinic, not arrange to meet
people directly outside of the clinic, and not deal any
drugs in the area directly surrounding the clinic. 4) The
study team had to strike a Neighbourhood Advisory Com-
mittee (NAC), to which any interested groups in the area
surrounding the clinic (businesses and housing strata-
committees) were to be invited to participate. This com-
mittee was to meet on a regular basis, with Vancouver
study team members in attendance, so that they could
voice any concerns about the study and its effect, if any,
on the neighbourhood. The NAC started meeting in early
2005 and continued to meet until the clinical portion of
the trial completed. During this time the NAC did not
raise any concerns regarding the study. As a matter of fact,Harm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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the NAC describes the study as a 'non-event' in terms of its
effects on the community. This is to be expected consider-
ing the study is only able to treat 192 of the estimated
5,000 IDUs in the DTES. 5) Due to concerns raised over
the 'honey pot effect', specifically those addicted to heroin
moving into the already crowded DTES from other areas
in order to access the study, the study was restricted to
recruiting only those participants who lived within a one-
mile radius of the study site. While this restriction cer-
tainly limited recruitment to participants that were truly
the most visible chronic opioid addicts, it also excluded
many people with a heroin addiction who truly did need
help, were ready for treatment, and met all of the inclu-
sion criteria except the latter residency restriction. To our
knowledge no other clinical trial has had restrictions on
recruitment by geographic area placed upon it by the City
of Vancouver. All of these conditions speak to the chronic
institutionalized discrimination affecting drug users.
It is important to note that the residency criteria for enter-
ing the study was relaxed somewhat in the late summer of
2005. The research team and the City of Vancouver agreed
to expand the definition of 'residency' to include people
who could prove that they were clearly accessing services
on a regular basis within the one-mile catchment area. The
City required that the NAC approve of this change, which
happened in September 2005, before the change could
take affect.
Lastly, as part of our development permit, we were
required to provide 'elevation drawings' to the storefront
and façade of the study site with the stated intent being to
'improve the appearance of the storefronts to ensure
pedestrian interest'. This condition is ironic because the
City and the Federal Government did not want to draw
attention to the site or what was happening within its
walls.
Health Canada requirements
Aside from the aforementioned City requirements, in
order to gain the approval of the Office of Controlled Sub-
stances of Health Canada and obtain a Section 56 exemp-
tion, additional security requirements had to be met at the
study sites. As previously mentioned, the Section 56
exemption is the same exemption that Vancouver's Super-
vised Injection Site is required to have. However, due to
the NAOMI study storing, preparing, and administering
narcotics many additional security features were required
for the study sites.
The first restriction placed upon the study team was one
of confidentiality. Health Canada's Office of Controlled
Substances was very concerned that news of the NAOMI
study would get out to the Canadian public in advance of
their final approval and granting of the Section 56 exemp-
tion. They did not want news of the NAOMI trial applica-
tion in the press while it was still under consideration for
approval. Due to this restriction, when news of the first
site broke and media were informed about the site and
our intentions, the study team was not able to comment
to the media about the specifics of the trial, nor that it was
a scientifically approved RCT with ethical approval at all
of the study sites. This inability to consult with the local
community played a large part in the loss of the first study
site. This issue continued to be problematic until, finally,
there was agreement that the need to inform and educate
the public about the trial outweighed any possible bene-
fits that could be gained by remaining silent on the issue.
In addition to the confidentiality issue, Health Canada
put forward a host of additional security restrictions
which needed to be satisfied in order to gain a Section 56
exemption. The level of security required is determined by
the maximum street value of heroin to be stored at the
facility at any one time based on Health Canada estimates
of street value. However, contrary to common knowledge
about the street value of heroin (approximately $30 CDN
per 0.25 gram on June 13, 2008), Health Canada policy
valued heroin at $3 million per kg or approximately $750
per 0.25 gram, roughly twenty-five times more than the
actual street value.
This Health Canada policy resulted in the security
required for the study sites to soar to a whole new level.
The long list of Health Canada requirements included:
specially reinforced glass; a sealed medication room with
a specially designed one-way tray through which nurses
passed medications to participants; a chute in the reverse
direction through which participants returned used
syringes under observation; multiple security cameras
covering every angle, including overlap, to ensure that no
heroin was diverted, either by participants or staff; vesti-
bules to be built so that there was a 'secured' area and peo-
ple could not directly enter the clinic through one door –
this would provide the clinic staff with the opportunity to
vet, via security camera, those who entered the vestibule
before they were actually permitted access to the clinic
proper; although the site was only able to keep a three day
supply of heroin on the premises due to other Health
Canada restrictions, the heroin had to be stored in a
locked fridge within a safe to which only the clinic man-
agers had keys and passwords; specific safety training was
required for all staff including how to deal with a hostage
situation (Health Canada was concerned about members
of organized crime wanting to obtain the heroin stored at
the clinic); and the development of a specific and detailed
system to log and monitor every milligram of heroin from
the time of delivery to administration. In addition, every
time point had to be recorded for each participant visit
including when they enter the premises, when they pass
their pre-assessment, when they began and complete
administering their dose, whether the patient left any drugHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
Page 8 of 14
(page number not for citation purposes)
visible in the syringe, when they pass their post-assess-
ment, when they are discharged, and any other interaction
with study nurses, physicians, social workers, addiction
counsellors, medical office assistants, or clinic managers.
As the Vancouver site was not attached to an institution
such as a hospital, it had additional requirements placed
upon it, including: only a very select few could have keys
and passwords to enter the clinic when it was not in oper-
ation – clinic staff would have to be granted entry access
from a clinic manager already inside the clinic; and vibra-
tion sensors had to be installed on all of the outside doors
and windows. Given the nature of all of these require-
ments, there were significant corresponding costs associ-
ated with establishing these clinics that could not be
covered by the original scientific grant. These additional
security requirements, as well as the change in the heroin
compound that Health Canada would allow the study
team to utilize, resulted in roughly an additional $2 mil-
lion Cdn needing to be raised in order to establish, recruit
into, run, and complete the study. The final funding for
the study is derived from several different funding part-
ners, each with their own restrictions on expenses and
individual reporting requirements, thus necessitating
internal accounting staff dedicated to the management of
the NAOMI study budget, including transaction process-
ing and financial reporting. The final budget for the study,
including one-time costs such as renovations and security,
is approximately $10.5 million Cdn.
The last issue to be resolved with Health Canada was how
the heroin would be delivered to the clinics. While it was
acceptable to have the heroin delivered to the hosting,
institutional pharmacies by regular couriers who rou-
tinely deliver medicines, Health Canada was very specific
that the study medication be delivered to the study sites
by armoured car. In fact, there was a point when the study
was not going to proceed despite the work to-date because
Health Canada was insisting on daily deliveries of the
study drug (meaning that only a one day supply of drug
could be stored on-site as opposed to a three day supply).
This resulted in lengthy discussions during which the
study team outlined to Health Canada that should a strike
occur (at the armoured car company), or should weather
impede the daily delivery of study medication (which was
very likely at some point in Montréal), then the study
team would not be able to provide the medication as out-
lined in the protocol. Further, this would be considered a
breach of ethics as well as a breach of Good Clinical Prac-
tice (especially since such a delay could be foreseen and
precautions taken against it).
Finally, a compromise was reached. Health Canada and
the researchers were able to come to an agreement on the
amount of heroin that could be stored at the clinical sites
at any one time, thus no longer necessitating daily
armoured car deliveries.
Other challenges – our neighbours to the south
One of the other challenges is the proximity and close
relationship of Canada and the US. While there are many
supporters of harm reduction policies and practices in the
US, the Bush administration is not among them and is
well known for its lack of support for important harm
reduction programs such as needle exchange programs, as
well other addiction treatment initiatives. When it comes
to clinical trials providing heroin for treatment of heroin
addiction or Supervised Injection Sites, there is no ques-
tion about how the Bush administration feels about such
interventions. In 2003 US Drug Czar John Walters referred
to Vancouver's Supervised Injection Site as "state spon-
sored personal suicide" [51], and in interviews on Cana-
dian television made what some would call veiled threats
saying that it would be "regrettable" if Canada started hav-
ing trouble getting their goods across the (US/Canada)
border [52].
While the general expectation is that politics should not
influence science and research, the fact is that politics can
play a significant part. Aside from the political issues ear-
lier identified with respect to the eligibility criteria for the
study, there were, and continue to be, politics around
areas of harm reduction. In the Canadian context, the cur-
rent Conservative Federal Government has been working
to strengthen ties with the US Government and is often
unwilling to confront the US government, especially for a
cause as controversial as HAT.
In 2004 the NAOMI team in Vancouver received a request
from the US Consulate in Vancouver for a meeting. US
Embassy officials visited the Principal Investigator and a
member of the NAOMI study team and, while the first
part of the conversation was centred around the study
itself, the officials also requested (and were denied) a list
of our US collaborators, specifically the US members of
the NAOMI Working Groups established in 1998.
Recruitment into NAOMI
In March 2005 recruitment into NAOMI commenced in
both cities. A lot of time and energy was spent on devel-
oping recruitment strategies. Due to the nature of the
study, and also because the study had been receiving
media attention prior to the start of recruitment, the study
team expected a deluge of calls once the recruitment lines
were open. With only a relatively small amount of
research assistants available due to budget constraints, the
phone lines were initially open two days per weeks for two
hours at a time. Posters describing the basic entry criteria
into NAOMI, the call in telephone numbers, and the
hours when the phones would be manned, were put upHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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around the DTES and in the City of Montréal, at needle
exchanges, community services and at VANDU (the Van-
couver Network of Drug Users). However, the expected
deluge of calls did not materialize. Some of the factors
leading to this were that: 1) many of the people NAOMI
was trying to reach were homeless; 2) limited access to tel-
ephones during the few hours the lines were open; 3) the
gag order imposed by Health Canada before the study
began had limited general education about the NAOMI
study; and 3) some doctors and community services/
organizations were incorrectly informing potential partic-
ipants that the study was already full. In response to this,
a new recruitment strategy needed to be developed
quickly.
The first change was to open up the recruitment lines dur-
ing normal business hours. The study teams also designed
new posters, created a schedule to regularly go out into the
community and replace torn posters, and hired outreach
workers. These outreach workers were charged with going
into the community and talking with users. They visited
needle exchanges, community centres, local organiza-
tions, and the Supervised Injection Site (in Vancouver).
Outreach workers would conduct a 'pre-screening' ques-
tionnaire to determine if a person might potentially qual-
ify for the study, and would then book an appointment or
even accompany the participant to the research office
where full eligibility could be firmly determined.
In addition to the outreach workers, team members con-
ducted information sessions for community groups and
services, as well as for groups of doctors, nurses and other
workers in the communities and in other addiction are-
nas. In order to reach the population that the NAOMI
study was seeking, advertisements were placed in the local
'free' papers, team members wore NAOMI t-shirts when
they were out in the community, recruitment and infor-
mation sessions were held where users were known to
congregate, and matchbooks were created and distributed
which listed the basic entry criteria into the study and the
telephone call-in numbers.
Not surprisingly, recruitment into the study took longer
than expected, finishing in April 2007. However, the main
impediment to recruitment was not the factors listed
above, but rather the highly restrictive nature of the inclu-
sion/exclusion criteria. It is noteworthy that delays in
recruitment have been a barrier in most of the trials aimed
at hard-to-reach drug using populations [53,54]. For
example, the German HAT RCT had to be extended an
additional year due to unexpected delays in recruitment
into the study [55]. In the case of NAOMI, the primary
barriers to study entry were in relation to previous addic-
tion treatment attempts and of not being on MMT at the
time of recruitment. The research assistants found that
many potential candidates had not reached a dose of 60
mg of methadone and/or had not remained on metha-
done for at least one month in their previous attempt(s).
Many individuals currently or recently on MMT but not
doing well came forward but were generally ineligible
because only those without any addiction treatment in the
last 6 months were able to participate. Other issues with
less impact were: not having resided for at least one year
in the city/site location, and for Vancouver participants,
not living within 1 mile of the clinic, not meeting the
(later) relaxed criteria of being a resident of the DTES, or
self-report of living within the one mile radius but not
able to obtain any documentation to verify the claim.
In Montréal, some of the issues surrounding recruitment
differed from the Vancouver site. Unlike Vancouver, Mon-
tréal's heroin users are spread over the island and there is
no large concentration of heroin addicts in one area com-
parable to the DTES. Also, without a central provincial
prescription database like Pharmanet in British Colum-
bia, obtaining the required verification of previous MMT
treatments for potential Montréal participants was diffi-
cult. Further, because Montréal's IDU population is fairly
spread out, many would have to travel up to an hour to
the clinic up to 3 times per day, which was not seen as very
attractive even with the provision of 'free' heroin.
At the end of the recruitment phase, the profile of the par-
ticipants who entered the NAOMI trial represented some
of the most chronic and marginalized opiate users in Van-
couver and Montréal [56].
Working with the media
Another challenge relating to NAOMI has been media
attention. Since publicly announcing the start of the trial,
the study has received considerable attention in local,
national and international media. While media interest
can be beneficial in raising the profile of harm reduction,
the media's need for headlines can throw off the balance
between scientific integrity and public education.
Treating heroin addiction with heroin tends to evoke a
knee-jerk reaction. Lack of understanding, restrictions on
time and resources, and the need for a catchy headline
often lead to sensationalism by the media. As previously
mentioned, opposition both within Canada and the US
also contributed to misleading reports from local,
national, and international media. The resulting focus has
been on a seeming shift in Canadian drug policy in direct
contradiction to the US war on drugs, rather than on the
scientific or medical merits of the NAOMI study.
With the NAOMI study being the only study of its kind in
North America, and with its two study sites located within
close proximity to the Canada/US border, increasedHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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media attention was unavoidable. Despite the fact that the
NAOMI study targets a very specific and marginalized
group within restricted geographic locations, regular
bursts in media attention have required the team to
extend strategic communications and outreach to a much
broader audience.
Some of issues raised in opposition to NAOMI are similar
to those raised for HAT in general. Many of them are
based on fear and misinformation, while others are based
on different moral values. Like many new treatment
modalities, critics exist who are opposed to NAOMI as
well as HAT. These criticisms are seen as improvement
opportunities for those who support HAT. A lot has been
said about this issue, and the authors refer the readers to
the early papers that discuss this topic in depth [57-59].
One myth about HAT is that it is a better treatment then
MMT and thus would replace MMT. In fact, HAT is not
meant to replace MMT, but to be another available treat-
ment option. One that would have a small but very
important role in the addiction treatment system [46].
Even in two of the three countries where HAT exists as a
regular program, participants in the program account for
less than 10% of those in substitution treatment in those
countries [31,45]. Another common myth is that HAT
patients will start using more cocaine (and/or other
drugs) because they no longer have to purchase heroin.
The results of all the RCTs showed that the use of cocaine
remains stable among HAT patients or even declines
[37,40,55,60].
Also an issue for some of the critics of HAT is that heroin
is a respiratory depressant and daily injection is less safe
than non-administration [40,41]. While injecting three
times per day, or even daily, is clearly more harmful than
not injecting, the analysis of patient safety should take
into account that if the patient is not receiving HAT he/she
would likely be injecting street heroin (cut with other
additives) in an unsafe environment, not to mention the
illegal activity that many enter into in order to purchase
their drug(s). This rationale is supported by the Swiss
study where in a seven-year period the mortality rate of
the Swiss participants was 1% per year, which is very low
compared to the general mortality ratio of Swiss opioid
users (2.5–3%) [61].
Further complicating the issue, North America's only
Supervised Injection Site (Insite) operates only blocks
away from NAOMI's Vancouver site. This had lead to con-
fusion amongst media and in turn the public who may
not fully understand the difference between NAOMI (a
randomized controlled clinical trial) and the Supervised
Injection Site (an important local harm reduction initia-
tive).
Science and media work in different ways and have differ-
ent priorities. Bridging this communications gap can
prove to be challenging and frustrating. The NAOMI team
addressed this issue through a concerted effort to educate
local communities, to maintain a low profile nationally,
and to commit to scientifically based messaging.
Due to these evolving issues the need to bring a Commu-
nications consultant on board was identified in order to
help define a response and to respond to media. This per-
son was charged with putting together the text for a study
website http://www.naomistudy.ca, writing press releases,
responding to basic media queries and arranging inter-
views which became a huge part of the overall NAOMI
study. While some journalists presented thoughtful and
engaging perspectives on heroin therapy, incomplete and
intended-to-shock media reports, not only within Canada
but also internationally, continued to stir emotions and
increase anxiety among local communities, police, vari-
ous levels of government, and our neighbours to the
south. Having someone on the team to help manage and
respond to these types of issues was very beneficial.
The NAOMI team's media strategy continues to be to
respond to media whilst committing to an unwavering
focus on the scientific aspects of the study. As discussed
earlier, the team also conducted community consultation
meetings and made numerous presentations to local serv-
ices organizations such as the Vancouver Area Network of
Drug Users (VANDU), and to local community organiza-
tions, the Provincial Government and the Federal Govern-
ment. In addition, Community Advisory Boards/
Committees (CABs) were established in Vancouver and
Montréal. The Vancouver CAB included representatives of
local community groups such as Grief to Action and
VANDU, the Provincial Health Officer, and also repre-
sentatives from the Royal Canadian Mounted Police, Van-
couver Police Department, British Columbia Ministries of
Health and Attorney General, British Columbia Centre for
Disease Control, and the City of Vancouver. The Montréal
CAB had a similar make-up comprising of representatives
from municipal, provincial and federal governments and
police, health authorities, pharmacists and physicians,
public security, ex-injection drug users, as well as repre-
sentatives from addiction treatment centres and the Uni-
versité de Montréal.
Over time, headlines and attitudes shifted from "Clinical
disorder on our northern border" (The Hoya, Georgetown
University) to "Why it makes sense to give them heroin"
(The Globe & Mail, Canada). More recently, the Vancou-
ver Courier published an article on NAOMI entitled "End
of NAOMI wastes research" (April 2, 2008) describing
that the study was due to finish this year and the chancesHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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of HAT being turned into a government supported pro-
gram were unlikely.
NAOMI – status report
The last of NAOMI's 251 participants completed the clin-
ical portion of the study in June 2008. While the Montréal
clinic is now closed, part of the Vancouver clinic remains
open and is now functioning as a small MMT clinic.
At the end of the 12-month period of active treatment,
participants were transitioned to available therapies in the
community, primarily MMT. Thus, even those who were
responding to HAT had to stop this treatment and go back
to the same options that had not worked for them in the
past because the study team could not legally continue to
prescribe DAM outside of the clinical trial treatment
period. Retention in treatment at the 12-month point was
significantly higher in the injection arm than the oral arm.
Results of the primary outcomes were released publicly on
October 17, 2008 and are available on the study website
at http://www.naomistudy.ca (scientific publication
pending).
Compassionate access to DAM for a small sample of
NAOMI participants who were retained, responding, and
had benefited from HAT, was sought through Health Can-
ada's Special Access Programme. However, the requests
were denied as the Programme felt that 'there are other
options (i.e. marketed drugs) that we would consider
alternatives to diamorphine at this time'. The results of the
primary end points demonstrate that, like in other coun-
tries, HAT can attract, retain, and benefit this sub-popula-
tion. However, as the Federal Government, through
Health Canada, has denied compassionate access use to
DAM, HAT treatment is unavailable in Canada. Canada is
the only country where diamorphine has been tested for
addiction treatment and has been denied compassionate
use [62].
On a separate but related issue, recently the Supreme
Court of British Columbia ruled that Section 4(1) and
5(1) of the Canadian Controlled Drug and Substances Act
(CDSA) are inconsistent with section 7 of the Canadian
Charter of Rights, thus meaning that those sections of the
CDSA are of no force or effect. This translates to Vancou-
ver's Supervised Injection Site being able to remain open
despite Federal Government. Specifically, the judgement
grants "users and staff at the Supervised Injection Site, act-
ing in conformity with the operating protocol now in
effect, a constitutional exemption form the application of
ss. 4(1) and 5(1) of the CDSA." However, the Canadian
Federal Government is appealing this ruling [63].
While not all of the 18 month and 24 month follow-up
research interviews have been conducted as of yet, and the
results of these interviews are not expected to be dissemi-
nated until summer 2009, it appears that after the treat-
ment endpoint participants generally either have
returned, or are returning to, where they were at baseline.
In a few cases the treatment participants accessed through
the study acted as a springboard to more long-term stabil-
ity. However, it appears that a much larger proportion of
participants have returned, or are returning to, where they
were at when they first entered the study.
As previously mentioned, the Vancouver clinic is partially
open and is providing MMT to some NAOMI participants,
as well as other patients from the community. The study
team hopes that the clinic will also be prescribing hydro-
morphone in the future. While details have not been final-
ized, and funding remains an issue that needs to be
resolved, the team is hopeful that this opportunity will
pan out. However, the possibility of providing heroin
treatment seems less likely given the conservative nature
of those that would need to provide approval and given
the response to-date from Health Canada's Special Access
Program. Notwithstanding, the NAOMI team continues
to work to try and make access to heroin and/or hydro-
morphone available to NAOMI participants and hope-
fully others who are in need of, and want, treatment, and
who would be good candidates for a form of HAT therapy.
Conclusion
Despite the challenges surrounding NAOMI, the authors
firmly believe that the study was worth doing. Given the
political issues still surrounding HAT, the authors feel that
it was important to conduct a HAT RCT in Canada and
look at HAT in the Canadian context. Although HAT is not
approved it Canada at this time, the authors hope that this
will change one day given the NAOMI results, in combi-
nation with the other HAT trial results already published.
If any of the authors, or anyone else associated with the
study, were to ever doubt whether NAOMI was worth
doing, or the profound affect it had on some participants,
we need only to remember the words recently written to
the Principal Investigator of NAOMI by one of the
NAOMI participants:
"...I want to tell you what being a participant in this study
did for me. Initially it meant "free heroin". But over time it
became more, much more. NAOMI took much of the stress
out of my life and allowed me to think more clearly about
my life and future. It exposed me to new ideas, people (staff
and clients) that in my street life (read: stressful existence)
there was no time for.
After NAOMI, I was offered oral methadone, which I
refused. After going quickly downhill, I ended up hopeless
and homeless. I went into detox in April 2007, abstainedHarm Reduction Journal 2009, 6:2 http://www.harmreductionjournal.com/content/6/1/2
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from using for two months, then relapsed. In July 2008 I
again went to detox and I am presently in a treatment
center...
I am definitely not "out of the woods" yet, but I feel I am on
the right path. And this path started for me at the corner of
Abbott and Hastings in Vancouver...
Thank you and all who were involved in making NAOMI
happen. Without NAOMI, I wouldn't be where I am today.
I am sure I would be in a much worse place."
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